 |
|
|
Education
PhD; University of Amsterdam; 1998
MD; Warsaw University Medical School; 1991
Research Interests
- Cellular interactions during the development of Th1 and Th2 responses
- Role of DC in the induction of polarized Th1 and Th2 responses (DC as mediators of signal 3)
- Th1 and Th2 CD4 T cell subsets in cancer patients
- Impact of tumor cells on DC functions
- Use of polarized DC to induce therapeutic Th1 and CTl responses against cancer
- Modulation of DC functions by NK cells, CD4+ (Th) and CD8+ (CTL) T cells as a tool to modify DC activity in vivo
Research Summary
Dr. Kalinski is interested in the role of DC in the induction of polarized Th1 and Th2 responses (DC as mediators of "signal 3") in healthy donors and cancer patients. The research of his group addresses the impact of tumor cells on DC functions, and the resulting undesirable suppression of immune responses, as well as the means of counteracting tumor-related immunosuppression. In this last respect, the group of Dr. Kalinski, in collaboration with the groups of Drs. Storkus and Kirkwood, demonstrated that so-called type-1 polarized DC can induce desirable Th1 and CTL responses against melanoma cells in the blood of patients with cancer.
Another line of research is based on the recent demonstration of the modulation of DC functions by NK cells and CD8+ (CTL) T cells. Both types of these classical "effector cells" can activate and polarize immature DC, providing CD4+ (Th) cells with DC-transmitted signals supporting the development of Th1-type responses. These observations open a possibility to use NK and CD8+ T cells as a tool to modify DC activity in vivo.
The above findings led to the design of two clinical trials that will test the therapeutic efficacy of the cytokine-induced DC1 ( DC1) and NK cell-induced DC1 (DC1NK) in patients with advanced melanoma.
Current research of the group utilizes human, mouse, and nonhumate primate models to analyze the possibilities of using polarized DC to revert the immunosuppression and undesirable Th2 bias in cancer and AIDS.
Recent Publications
- Vieira, P.L., de Jong, E.C., Wierenga, E.A., Kapsenberg, M.L., and Kalinski, P. (2000). Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 164:4507.
- Mailliard, R.B., Egawa, S., Cai, Q., Wankowicz-Kalinska, A., Lotze, M.T., Kapsenberg, M.L., Storkus, W.J., and Kalinski, P. (2002). Helper function of CD8+ T cells in the development of Th1 responses: polarized dendritic cells mediate CD8 help for CD4+ T cells. J. Exp. Med. 195:473-483.
- O'Connell, P.J., Son, Y., Giermasz, A., Logar, A.J., Thomson, A.W., and Kalinski, P. (2003). Type-1 polarized nature of mouse liver CD8- and CD8+ dendritic cells: tissue-dependent differences offset CD8?-related dendritic cell heterogeneity. Eur. J. Immunol. 33:2007-2013.
- Mailliard, R.B., Son, Y., Redlinger, R., Coates, P.T., Giermasz, A., Morel, P.A., Storkus, W.J., and Kalinski, P. (2003). Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. J. Immunol., 171:2366-2373.
- Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski (2004). Alpha-type-1 Dendritic Cells (DC1): A Novel Immunization Tool with Optimized CTL-inducing Activity. Canc. Research 64: 5934-5937.
- Kalinski P., and M. Moser (2005). Consensual Immunity: Success-Driven Development of Type-1 and Type-2 responses. Nature Rev. Immunol. 5: 251-260.
- Kalinski, P., Mailliard, R.B., Giermasz, A., Zeh, H.J., Basse, P., Bartlett, D.L., Kirkwood, J.M., Lotze, M.T., and Herberman, R.B. (2005). Natrual killer-dendritic cell cross-talk in cancer immunotherapy. Expert. Opin. Biol. Ther. 5:1303-1315.
- Mailliard, R.B., Alber, S.M., Shen, H., Watkins, S.C., Kirkwood, J.M., Herberman, R.B., and Kalinski, P. (2005) IL-18-induced CD83+CCR7+ NK helper cells. J. Exp. Med. 202:941-953.
Dr. Kalinski's Lab
Last Updated: October 9, 2007
|
